What type of study is this?

This is a Literature Review study.

September 20, 2025Current Issues in Molecular BiologyOpen Access

Combination of the First-in-Class Imipridone ONC201 and Standard Anticancer Therapies as a Rational Approach for Therapeutic Benefit

View Full Paper

Ask AI

Bookmark

Authors

BSBaskar ShenoyManipal Academy of Higher Education MMMiloni MandaniNarsee Monjee Institute of Management Studies MCMeena ChintamaneniNarsee Monjee Institute of Management Studies

Discussion

Member takes

Implication

This review highlights the therapeutic potential of ONC201 in combination with other anticancer therapies, suggesting improved outcomes in various cancers.

Key Points

ONC201 demonstrated notable effectiveness against various cancers, suggesting potential benefits from combination therapies.
Preclinical studies reveal that ONC201 can synergize with standard anticancer therapies for greater tumor cell death.
The development of ONC201 is significant, given its FDA approval for the treatment of recurrent h3k27m-mutant diffuse midline glioma.
The unique pharmacophore of ONC201 allows it to effectively activate natural killer cells and target cancer cells selectively.

Cite This Study

Shenoy et al. (2025) studied this question.

synapsesocial.com/papers/68d469ce31b076d99fa66cb7 https://doi.org/10.3390/cimb47090775

View Full Paper

Ask AI

Bookmark

Implication

This review highlights the therapeutic potential of ONC201 in combination with other anticancer therapies, suggesting improved outcomes in various cancers.

Combination of the First-in-Class Imipridone ONC201 and Standard Anticancer Therapies as a Rational Approach for Therapeutic Benefit

Discussion

Member takes

Implication

Key Points

Cite This Study

Combination of the First-in-Class Imipridone ONC201 and Standard Anticancer Therapies as a Rational Approach for Therapeutic Benefit

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider